Success and safety of high infliximab trough levels in inflammatory bowel disease-Reference-Cited by-同舟云学术

Success and safety of high infliximab trough levels in inflammatory bowel disease

Published:2018-07-10 Issue:8 Volume:53 Page:940-946
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Drobne David¹²^ORCID,Kurent Tina¹,Golob Sasa¹,Svegl Polona¹,Rajar Polona¹,Terzic Sara³,Kozelj Matic¹,Novak Gregor¹,Smrekar Natasa¹,Plut Samo¹²,Sever Nejc¹,Strnisa Luka¹²,Hanzel Jurij¹,Brecelj Jernej²⁴,Urlep Darja⁴,Osredkar Josko⁵,Homan Matjaz²⁴,Orel Rok²⁴,Stabuc Borut¹²,Ferkolj Ivan¹²,Smid Alojz¹²

Affiliation:

1. Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;

2. Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;

3. Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia;

4. Department of Gastroenterology Hepatology and Nutrition, Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia;

5. Clinical Institute of Clinical Chemistry, Biochemistry University Medical Centre Ljubljana, Ljubljana, Slovenia

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2018.1486882

Reference23 articles.

1. Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease

2. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

3. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

4. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease

5. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis;The Journal of Clinical Pharmacology;2023-12-03

2. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels;Internal Medicine Journal;2023-05-20

3. Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies;Children;2023-03-28

4. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease;Therapeutic Drug Monitoring;2023-02-23

5. 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients;International Journal of Molecular Sciences;2023-02-16